Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 659.85 INR
Change Today -1.10 / -0.17%
Volume 2.3M
CIPLA On Other Exchanges
Natl India
As of 7:05 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

cipla ltd (CIPLA) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/10/15 - 752.85
52 Week Low
09/1/14 - 514.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CIPLA LTD (CIPLA)

Related News

No related news articles were found.

cipla ltd (CIPLA) Related Businessweek News

No Related Businessweek News Found

cipla ltd (CIPLA) Details

Cipla Limited manufactures and sells pharmaceutical and personal care products in India. It offers active pharmaceutical ingredients; and formulations in therapeutic areas, such as allergy, analgesic, anti-malarial, anti-infectives, cardiology, dermatology and cosmeceuticals, diabetology, gastroenterology, HIV-AIDS, hormones and steroids, iron chelators, musculoskeletal, neuropsychiatry, oncology, respiratory, urology, and women’s health, as well as nutritional and ophthalmic products. The company also provides veterinary products for various animals, including companion, equine, general care, livestock, and poultry. In addition, it offers inhaled medication and devices comprising dry powder inhalers, metered-dose inhalers, spacers and related devices, nasal sprays, nebulizers, and inhalation accessory devices. The company also exports raw materials, intermediates, prescription drugs, over-the-counter drugs, and veterinary products to approximately 170 countries worldwide. Cipla Limited was founded in 1935 and is based in Mumbai, India.

Founded in 1935

cipla ltd (CIPLA) Top Compensated Officers

Global Chief Executive Officer, Managing Dire...
Total Annual Compensation: 54.4M
Whole-Time Director, Member of Mergers & Acqu...
Total Annual Compensation: 12.0M
Chief Compliance Officer and Company Secretar...
Total Annual Compensation: 9.5M
Compensation as of Fiscal Year 2015.

cipla ltd (CIPLA) Key Developments

Cipla Appoints Prabir Jha as HR Head

Prabir Jha, who has recently quit Reliance Industries as its chief human resources officer, is reportedly considering an offer to join Cipla as head human resources. Jha, had joined RIL two years ago and was instrumental in several progressive HR measures including a five-day week, increased leave entitlements, extension of maternity leave and several other changes to simplify policies. Jha had joined RIL from Tata Motors.

Cipla Reportedly Mulls Acquisition Of Stake In Kremers

Cipla Limited (NSEI:CIPLA) reportedly seeking acquisition of stakes in Kremers Urban Pharmaceuticals Inc. from UCB S.A. (ENXTBR:UCB). Cipla has emerged as the sole Indian contender for Kremers Urban Pharmaceuticals Inc. which is pegged at around $1.3 billion. "Cipla is the only Indian bidder for KU but it is pitted against a few powerful private equity players. It also depends on whether Cipla is prepared to shell out a large amount in a single bid," an industry watcher told Economic Times. Lupin Limited (BSE:500257) and Torrent Pharmaceuticals Ltd. (BSE:500420) were named as the other two Indian parties that had initially shown interest but eventually opted out. One of them is China's conglomerate China Grand Group. UCB floated the divestiture of Kremers Urban in 2014. In response to questions from ET, a Cipla spokesperson said the company does not comment on any product or partner discussions. Kremers had sales of $463 million in 2014.

Cipla Limited Provides Earnings Guidance for the Fiscal Year 2016

Cipla Limited provided earnings guidance for the fiscal year 2016. For the fiscal year 2016, outlook of the company remains strong with 20% top-line growth. Margin guidance unchanged.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CIPLA:IN 659.85 INR -1.10

CIPLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 756.40 INR 0.00
Cadila Healthcare Ltd 1,929 INR 0.00
Piramal Enterprises Ltd 932.25 INR 0.00
Torrent Pharmaceuticals Ltd 1,615 INR 0.00
Wockhardt Ltd 1,351 INR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CIPLA Industry Range
Price/Earnings 32.2x
Price/Sales 4.0x
Price/Book 4.6x
Price/Cash Flow 24.1x
TEV/Sales 3.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CIPLA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at